135 related articles for article (PubMed ID: 32873419)
1. Immunotherapy-induced colitis: Could it be ulcerative colitis?
Moreno Moraleda I; Lázaro Sáez M; Diéguez Castillo C; Hernández Martínez Á
Gastroenterol Hepatol; 2021 Jan; 44(1):28-29. PubMed ID: 32873419
[No Abstract] [Full Text] [Related]
2. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
[No Abstract] [Full Text] [Related]
3. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
Jespersen H; Bjursten S; Ny L; Levin M
Lancet Oncol; 2018 Jun; 19(6):e327. PubMed ID: 29893264
[No Abstract] [Full Text] [Related]
4. Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis.
Miyashita A; Fukushima S; Tsukamoto H; Itai H; Miyamoto H; Nakahara S; Kubo Y; Kimura T; Kuriyama H; Ihn H
J Dermatol; 2019 Sep; 46(9):e339-e341. PubMed ID: 30908699
[No Abstract] [Full Text] [Related]
5. Management of immunotherapy colitis: Special considerations in the COVID-19 era.
Grover S; Bond SA; Mansour MK; Friedman S
Cancer; 2020 Nov; 126(21):4630-4633. PubMed ID: 32797685
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?
Pradère P; Boutros C; Scoazec JY; Dorfmüller P; Leroy-Ladurie F; Boulate D; Le Pavec J; Robert C
Eur J Cancer; 2018 Apr; 93():144-146. PubMed ID: 29402507
[No Abstract] [Full Text] [Related]
7. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
8. A Life-Threatening Cause of Colitis.
Jaswani TS; Grider DJ; Bern MJ
Gastroenterology; 2018 Jan; 154(1):35-36. PubMed ID: 28918915
[No Abstract] [Full Text] [Related]
9. Pembrolizumab-Induced Alopecia Areata.
Elshimy N; Blakeway E; Mitra A
Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
[No Abstract] [Full Text] [Related]
10. Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment.
Acaba-Berrocal LA; Lucio-Alvarez JA; Mashayekhi A; Ho AC; Dunn JP; Shields CL
JAMA Ophthalmol; 2018 Oct; 136(10):1205-1207. PubMed ID: 30054605
[No Abstract] [Full Text] [Related]
11. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
Donaldson M; Owen JL; Choi JN
JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
[No Abstract] [Full Text] [Related]
12. Diarrhoea during checkpoint blockade, not always colitis.
Koldenhof JJ; Suijkerbuijk KPM
Eur J Cancer; 2017 Dec; 87():216-218. PubMed ID: 28993041
[No Abstract] [Full Text] [Related]
13. Acute localised exanthematous pustulosis secondary to pembrolizumab.
Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
[No Abstract] [Full Text] [Related]
14. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
Arianayagam S; Ieremia E; Matin RN
Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
[No Abstract] [Full Text] [Related]
15. A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia.
Berger M; Amini-Adlé M; Crumbach L; Paubelle E; Dalle S
Eur J Cancer; 2019 Mar; 110():49-52. PubMed ID: 30739840
[No Abstract] [Full Text] [Related]
16. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
17. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
18. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
[No Abstract] [Full Text] [Related]
19. Generalized morphea in the setting of pembrolizumab.
Cheng MW; Hisaw LD; Bernet L
Int J Dermatol; 2019 Jun; 58(6):736-738. PubMed ID: 29931792
[No Abstract] [Full Text] [Related]
20. [Severe ipilimumab-induced ulcerative colitis remitting after infliximab therapy and secondary switching with pembrolizumab].
Yelehe-Okouma M; Granel-Brocard F; Hudziak H; Schmutz JL; Gillet P
Therapie; 2018; 73(3):291-293. PubMed ID: 29203065
[No Abstract] [Full Text] [Related]
[Next] [New Search]
